Human amniotic membrane mesenchymal stem cells-conditioned medium attenuates myocardial ischemia-reperfusion injury in rats by targeting oxidative stress.
Conditioned medium
Ischemic heart diseases
Mesenchymal stem cells
Myocardial ischemia/-reperfusion injury
Oxidative stress
Journal
Iranian journal of basic medical sciences
ISSN: 2008-3866
Titre abrégé: Iran J Basic Med Sci
Pays: Iran
ID NLM: 101517966
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
entrez:
25
11
2020
pubmed:
26
11
2020
medline:
26
11
2020
Statut:
ppublish
Résumé
Ischemic heart diseases (IHD) are one of the major causes of death worldwide. Studies have shown that mesenchymal stem cells can secrete and release conditioned medium (CM) which has biological activities and can repair tissue injury. This study aimed to investigate the effects of human amniotic membrane mesenchymal stem cells (hAMCs)-CM on myocardial ischemia/reperfusion (I/R) injury in rats by targeting oxidative stress. Male Wistar rats (40 rats, weighing 200-250 g) were randomly divided into four groups: Sham, myocardial infarction (MI), MI + culture media, and MI + conditioned medium. MI was induced by ligation of the left anterior descending coronary artery for 30 min. After 15 min of reperfusion, intramyocardial injections of hAMCs-CM or culture media (150 μl) were performed. At the end of the experiment, serum levels of cardiac troponin-I (cTn-I), myocardial levels of malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione peroxidase (GPx), as well as cardiac histological changes were evaluated. HAMCs-CM significantly decreased cTn-I and MDA levels and increased SOD and GPx activities ( This study showed that hAMCs-CM has cardioprotective effects in the I/R injury condition. Reduction of oxidative stress by hAMCs-CM plays a significant role in this context. Based on the results of this study, it can be concluded that hAMCs-CM can be offered as a therapeutic candidate for I/R injury in the future, but more research is needed.
Identifiants
pubmed: 33235703
doi: 10.22038/ijbms.2020.47572.10952
pmc: PMC7671430
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1453-1461Références
J Biol Chem. 1969 Nov 25;244(22):6049-55
pubmed: 5389100
World J Cardiol. 2018 Sep 26;10(9):74-86
pubmed: 30344955
Biomed Pharmacother. 2018 Jun;102:385-391
pubmed: 29573617
J Lab Clin Med. 1967 Jul;70(1):158-69
pubmed: 6066618
Pharmacol Ther. 2012 Feb;133(2):230-55
pubmed: 22138603
Cell Physiol Biochem. 2018;50(3):1123-1139
pubmed: 30355930
J Biol Chem. 2011 Mar 4;286(9):7468-78
pubmed: 21159781
Acta Physiol Scand Suppl. 1986;548:9-37
pubmed: 3019082
Anal Biochem. 1979 Jun;95(2):351-8
pubmed: 36810
Stem Cell Res. 2007 Nov;1(2):129-37
pubmed: 19383393
Methods Enzymol. 1981;77:325-33
pubmed: 7329310
Sci Rep. 2015 Nov 06;5:16295
pubmed: 26542315
Indian J Biochem Biophys. 1984 Apr;21(2):130-2
pubmed: 6490072
Am J Med Sci. 2007 Sep;334(3):197-205
pubmed: 17873534
Oxid Med Cell Longev. 2016;2016:1656450
pubmed: 27313825
Stem Cells Transl Med. 2015 May;4(5):448-58
pubmed: 25824141
Perfusion. 2015 Oct;30(7):565-71
pubmed: 25552273
PLoS One. 2011;6(12):e29246
pubmed: 22195033
J Physiol Biochem. 2017 Feb;73(1):111-120
pubmed: 27771871
J Cardiovasc Pharmacol Ther. 2018 Mar;23(2):174-183
pubmed: 28901167
J Heart Lung Transplant. 2011 Jan;30(1):95-102
pubmed: 21030271
J Cardiovasc Pharmacol Ther. 2020 May;25(3):240-250
pubmed: 31645107
Stem Cell Res. 2011 May;6(3):206-14
pubmed: 21419744
Clin Cardiol. 2008 Feb;31(2):67-71
pubmed: 18257021
J Mol Cell Cardiol. 2010 Jun;48(6):1215-24
pubmed: 20064522
J Stem Cells Regen Med. 2012 Nov 26;8(3):171-80
pubmed: 24693195